Sentence	entity_1	entity_2	entity_3	entity_4	entity_5	entity_6	entity_7	entity_8	entity_9	entity_10	entity_11	entity_12	entity_13	entity_14	entity_15	entity_16	entity_17	entity_18	entity_19	entity_20	entity_21	entity_22	json	split
AD: Alzheimer ' s disease; BF: Boutonnese fever; CCR5: CC chemokine receptor 5; COX - 2: Cyclo - oxygenase 2; CRP: C reactive protein; CVD: Cardiovascular disease; HSPs: Heat - shock proteins; INF - γ: Interferon - γ; IL - 6: Interleukin - 6; IL - 10: Interleukin - 10; 5 - LO: 5 - lipoxygenase; LPS: Lipopolysaccharide; LTs: Leukotrienes; MI: Myocardial infarction; ox - LDL: Oxidized - Low Density Lipoproteins; PC: Prostate cancer; PGs: Prostaglandins; SNPs: Single nucleotide polymorphisms; TLR4: Toll - like - receptor - 4; TNF - α: Tumor necrosis factor - α.	Alzheimer ' s disease,4,25,Disease/Disorder	CCR5,49,53,Gene/Protein	COX - 2,80,87,Gene/Protein	C reactive protein,115,133,Gene/Protein	CVD,135,138,Disease/Disorder	Cardiovascular disease,140,162,Disease/Disorder	INF - γ,193,200,Gene/Protein	Interferon - γ,202,216,Gene/Protein	IL - 6,218,224,Gene/Protein	Interleukin - 6,226,241,Gene/Protein	IL - 10,243,250,Gene/Protein	Interleukin - 10,252,268,Gene/Protein	5 - LO,270,276,Gene/Protein	5 - lipoxygenase,278,294,Gene/Protein	Myocardial infarction,344,365,Disease/Disorder	PC,414,416,Disease/Disorder	Prostate cancer,418,433,Disease/Disorder	Prostaglandins,440,454,Chemical/Drug	TLR4,495,499,Gene/Protein	Toll - like - receptor - 4,501,527,Gene/Protein	TNF - α,529,536,Gene/Protein	Tumor necrosis factor - α,538,563,Gene/Protein	"[{""token"": ""Alzheimer ' s disease"", ""start_span"": 4, ""end_span"": 25, ""type"": ""Disease/Disorder""}, {""token"": ""CCR5"", ""start_span"": 49, ""end_span"": 53, ""type"": ""Gene/Protein""}, {""token"": ""COX - 2"", ""start_span"": 80, ""end_span"": 87, ""type"": ""Gene/Protein""}, {""token"": ""C reactive protein"", ""start_span"": 115, ""end_span"": 133, ""type"": ""Gene/Protein""}, {""token"": ""CVD"", ""start_span"": 135, ""end_span"": 138, ""type"": ""Disease/Disorder""}, {""token"": ""Cardiovascular disease"", ""start_span"": 140, ""end_span"": 162, ""type"": ""Disease/Disorder""}, {""token"": ""INF - \u03b3"", ""start_span"": 193, ""end_span"": 200, ""type"": ""Gene/Protein""}, {""token"": ""Interferon - \u03b3"", ""start_span"": 202, ""end_span"": 216, ""type"": ""Gene/Protein""}, {""token"": ""IL - 6"", ""start_span"": 218, ""end_span"": 224, ""type"": ""Gene/Protein""}, {""token"": ""Interleukin - 6"", ""start_span"": 226, ""end_span"": 241, ""type"": ""Gene/Protein""}, {""token"": ""IL - 10"", ""start_span"": 243, ""end_span"": 250, ""type"": ""Gene/Protein""}, {""token"": ""Interleukin - 10"", ""start_span"": 252, ""end_span"": 268, ""type"": ""Gene/Protein""}, {""token"": ""5 - LO"", ""start_span"": 270, ""end_span"": 276, ""type"": ""Gene/Protein""}, {""token"": ""5 - lipoxygenase"", ""start_span"": 278, ""end_span"": 294, ""type"": ""Gene/Protein""}, {""token"": ""Myocardial infarction"", ""start_span"": 344, ""end_span"": 365, ""type"": ""Disease/Disorder""}, {""token"": ""PC"", ""start_span"": 414, ""end_span"": 416, ""type"": ""Disease/Disorder""}, {""token"": ""Prostate cancer"", ""start_span"": 418, ""end_span"": 433, ""type"": ""Disease/Disorder""}, {""token"": ""Prostaglandins"", ""start_span"": 440, ""end_span"": 454, ""type"": ""Chemical/Drug""}, {""token"": ""TLR4"", ""start_span"": 495, ""end_span"": 499, ""type"": ""Gene/Protein""}, {""token"": ""Toll - like - receptor - 4"", ""start_span"": 501, ""end_span"": 527, ""type"": ""Gene/Protein""}, {""token"": ""TNF - \u03b1"", ""start_span"": 529, ""end_span"": 536, ""type"": ""Gene/Protein""}, {""token"": ""Tumor necrosis factor - \u03b1"", ""start_span"": 538, ""end_span"": 563, ""type"": ""Gene/Protein""}]"	test
Although RR was not significantly different in subjects with EGFR wild type ( WT ), the DCR was significantly lower in ILD and IPF than in non - ILD patients. Table 2Response to first - line chemotherapy / molecular targeted therapyNon - ILD ( n = 165) ILDAll ILD ( n = 53) P ( vs. non - ILD) IPF ( n = 34) P ( vs. non - ILD) Number of cycles of chemotherapy, average ( range) 5 ( 1 – 24) 4 ( 1 – 34) 0. 11213 ( 1 – 12) 0. 0014Number of patients who received fewer than three cycles (%) 61 ( 37 %) 38 ( 72 %)< 0. 000128 ( 82 %)< 0. 0001All patients CR400 PR861910 SD51177 PD221515 NA222 Response rate55% 37% 0. 036331% 0. 0193 Disease control rate87% 71% 0. 018053% 0. 0001Patients without EGFR mutation CR200 PR461810 SD46177 PD161515 NA222 Response rate44% 35% 0. 391031% 0. 2278 Disease control rate85% 67% 0. 030453% 0. 0004 ILD interstitial lung disease, IPF idiopathic pulmonary fibrosis, CR complete response, PR partial response, SD stable disease, PD progressive disease, NA not assessed	EGFR,61,65,Gene/Protein	ILD,119,122,Disease/Disorder	IPF,127,130,Disease/Disorder	ILD,145,148,Disease/Disorder	ILD,238,241,Disease/Disorder	ILD,253,256,Disease/Disorder	ILD,260,263,Disease/Disorder	IPF,293,296,Disease/Disorder	ILD,321,324,Disease/Disorder	PR861910,555,563,Chemical/Drug	SD51177,564,571,Chemical/Drug	PD221515,572,580,Chemical/Drug	EGFR,690,694,Gene/Protein	PR461810,710,718,Chemical/Drug	SD46177,719,726,Chemical/Drug	PD161515,727,735,Chemical/Drug	ILD,829,832,Disease/Disorder	interstitial lung disease,833,858,Disease/Disorder	IPF,860,863,Disease/Disorder	idiopathic pulmonary fibrosis,864,893,Disease/Disorder	PD,957,959,Disease/Disorder	progressive disease,960,979,Disease/Disorder	"[{""token"": ""EGFR"", ""start_span"": 61, ""end_span"": 65, ""type"": ""Gene/Protein""}, {""token"": ""ILD"", ""start_span"": 119, ""end_span"": 122, ""type"": ""Disease/Disorder""}, {""token"": ""IPF"", ""start_span"": 127, ""end_span"": 130, ""type"": ""Disease/Disorder""}, {""token"": ""ILD"", ""start_span"": 145, ""end_span"": 148, ""type"": ""Disease/Disorder""}, {""token"": ""ILD"", ""start_span"": 238, ""end_span"": 241, ""type"": ""Disease/Disorder""}, {""token"": ""ILD"", ""start_span"": 253, ""end_span"": 256, ""type"": ""Disease/Disorder""}, {""token"": ""ILD"", ""start_span"": 260, ""end_span"": 263, ""type"": ""Disease/Disorder""}, {""token"": ""IPF"", ""start_span"": 293, ""end_span"": 296, ""type"": ""Disease/Disorder""}, {""token"": ""ILD"", ""start_span"": 321, ""end_span"": 324, ""type"": ""Disease/Disorder""}, {""token"": ""PR861910"", ""start_span"": 555, ""end_span"": 563, ""type"": ""Chemical/Drug""}, {""token"": ""SD51177"", ""start_span"": 564, ""end_span"": 571, ""type"": ""Chemical/Drug""}, {""token"": ""PD221515"", ""start_span"": 572, ""end_span"": 580, ""type"": ""Chemical/Drug""}, {""token"": ""EGFR"", ""start_span"": 690, ""end_span"": 694, ""type"": ""Gene/Protein""}, {""token"": ""PR461810"", ""start_span"": 710, ""end_span"": 718, ""type"": ""Chemical/Drug""}, {""token"": ""SD46177"", ""start_span"": 719, ""end_span"": 726, ""type"": ""Chemical/Drug""}, {""token"": ""PD161515"", ""start_span"": 727, ""end_span"": 735, ""type"": ""Chemical/Drug""}, {""token"": ""ILD"", ""start_span"": 829, ""end_span"": 832, ""type"": ""Disease/Disorder""}, {""token"": ""interstitial lung disease"", ""start_span"": 833, ""end_span"": 858, ""type"": ""Disease/Disorder""}, {""token"": ""IPF"", ""start_span"": 860, ""end_span"": 863, ""type"": ""Disease/Disorder""}, {""token"": ""idiopathic pulmonary fibrosis"", ""start_span"": 864, ""end_span"": 893, ""type"": ""Disease/Disorder""}, {""token"": ""PD"", ""start_span"": 957, ""end_span"": 959, ""type"": ""Disease/Disorder""}, {""token"": ""progressive disease"", ""start_span"": 960, ""end_span"": 979, ""type"": ""Disease/Disorder""}]"	train
IPA, ingenuity pathway analysis; EA, European - American; AA, African - American; RBP +, anti - RNA - binding - protein ( RBP) antibody positive; RBP −, RBP antibody negative; eIF2, eukaryotic initiation factor 2; IRF, interferon - regulatory factor; mTOR, mammalian target of rapamycin; TNFR2, tumor necrosis factor receptor 2; eIF4, eukaryotic initiation factor 4; RIG1, retinoic acid - inducible gene 1; PI3K, phosphatidylinositol 3 - kinase; OX40 = CD134.	RBP,82,85,Gene/Protein	RNA - binding - protein,96,119,Gene/Protein	RBP,122,125,Gene/Protein	antibody,127,135,Gene/Protein	RBP,146,149,Gene/Protein	RBP,153,156,Gene/Protein	antibody,157,165,Gene/Protein	eIF2,176,180,Gene/Protein	eukaryotic initiation factor 2,182,212,Gene/Protein	IRF,214,217,Gene/Protein	interferon - regulatory factor,219,249,Gene/Protein	mTOR,251,255,Gene/Protein	mammalian target of rapamycin,257,286,Gene/Protein	TNFR2,288,293,Gene/Protein	tumor necrosis factor receptor 2,295,327,Gene/Protein	eIF4,329,333,Gene/Protein	eukaryotic initiation factor 4,335,365,Gene/Protein	RIG1,367,371,Gene/Protein	retinoic acid - inducible gene 1,373,405,Gene/Protein	PI3K,407,411,Gene/Protein	phosphatidylinositol 3 - kinase,413,444,Gene/Protein	OX40,446,450,Gene/Protein	"[{""token"": ""RBP"", ""start_span"": 82, ""end_span"": 85, ""type"": ""Gene/Protein""}, {""token"": ""RNA - binding - protein"", ""start_span"": 96, ""end_span"": 119, ""type"": ""Gene/Protein""}, {""token"": ""RBP"", ""start_span"": 122, ""end_span"": 125, ""type"": ""Gene/Protein""}, {""token"": ""antibody"", ""start_span"": 127, ""end_span"": 135, ""type"": ""Gene/Protein""}, {""token"": ""RBP"", ""start_span"": 146, ""end_span"": 149, ""type"": ""Gene/Protein""}, {""token"": ""RBP"", ""start_span"": 153, ""end_span"": 156, ""type"": ""Gene/Protein""}, {""token"": ""antibody"", ""start_span"": 157, ""end_span"": 165, ""type"": ""Gene/Protein""}, {""token"": ""eIF2"", ""start_span"": 176, ""end_span"": 180, ""type"": ""Gene/Protein""}, {""token"": ""eukaryotic initiation factor 2"", ""start_span"": 182, ""end_span"": 212, ""type"": ""Gene/Protein""}, {""token"": ""IRF"", ""start_span"": 214, ""end_span"": 217, ""type"": ""Gene/Protein""}, {""token"": ""interferon - regulatory factor"", ""start_span"": 219, ""end_span"": 249, ""type"": ""Gene/Protein""}, {""token"": ""mTOR"", ""start_span"": 251, ""end_span"": 255, ""type"": ""Gene/Protein""}, {""token"": ""mammalian target of rapamycin"", ""start_span"": 257, ""end_span"": 286, ""type"": ""Gene/Protein""}, {""token"": ""TNFR2"", ""start_span"": 288, ""end_span"": 293, ""type"": ""Gene/Protein""}, {""token"": ""tumor necrosis factor receptor 2"", ""start_span"": 295, ""end_span"": 327, ""type"": ""Gene/Protein""}, {""token"": ""eIF4"", ""start_span"": 329, ""end_span"": 333, ""type"": ""Gene/Protein""}, {""token"": ""eukaryotic initiation factor 4"", ""start_span"": 335, ""end_span"": 365, ""type"": ""Gene/Protein""}, {""token"": ""RIG1"", ""start_span"": 367, ""end_span"": 371, ""type"": ""Gene/Protein""}, {""token"": ""retinoic acid - inducible gene 1"", ""start_span"": 373, ""end_span"": 405, ""type"": ""Gene/Protein""}, {""token"": ""PI3K"", ""start_span"": 407, ""end_span"": 411, ""type"": ""Gene/Protein""}, {""token"": ""phosphatidylinositol 3 - kinase"", ""start_span"": 413, ""end_span"": 444, ""type"": ""Gene/Protein""}, {""token"": ""OX40"", ""start_span"": 446, ""end_span"": 450, ""type"": ""Gene/Protein""}]"	train
